Search - tctmd.com

Displaying 1 - 20 of 184

Sort: Relevancy | Date

News Daily News

Nearly 150 Million US Adults Eligible for CKM Syndrome Meds

Caitlin E. Cox

February 02, 2026

News Daily News

Previewing 30-Year ASCVD Risk May Open Door to Earlier Treatment

Yael L. Maxwell

January 21, 2026

News Daily News

JACC Debuts Data Digest on CV Health in the United States

Caitlin E. Cox

January 12, 2026

News Daily News

Weight Regained Within 18 Months of Stopping GLP-1 Drugs

Michael O'Riordan

January 08, 2026

News Daily News

Year in Review: Top Prevention Stories of 2025

Michael O'Riordan

December 24, 2025

News Features

Year in Review: Women’s Heart Health in the Spotlight

Caitlin E. Cox

December 23, 2025

News Daily News

SURPASS-CVOT Published: Large Trial Confirms CVD Efficacy of Tirzepatide

Michael O'Riordan

December 18, 2025

News Daily News

Patients With Obesity Get Biggest Benefit from Evolocumab: FOURIER

Michael O'Riordan

December 12, 2025

News Daily News

Reversal of Childhood Overweight May Prevent Later CHD Risks

Todd Neale

December 03, 2025

News Daily News

WHO Endorses Treating Obesity in Adults With GLP-1s

Todd Neale

December 01, 2025

News Opinion CV Team Dispatch

October 2025 Dispatch for the CV Team

L.A. McKeown

October 25, 2025

News Daily News

Semaglutide’s CV Effects Only Partially Tied to Weight Loss: SELECT Analysis

Yael L. Maxwell

October 24, 2025

News Daily News

High Aerobic Fitness Linked to Less Chronic Disease in Later Life

Michael O'Riordan

October 10, 2025

News Daily News

Risk Factors Present in Nearly All Patients Who Develop CVD

Michael O'Riordan

October 02, 2025

News Daily News

Better Outcomes and Lower Cost with Bariatric Surgery Over GLP-1s

Michael O'Riordan

September 18, 2025

News Daily News

Half of Patients Stop Semaglutide for Weight Loss by 1 Year

Todd Neale

September 18, 2025

News Daily News

AI-Supported Coaching Shows Promise for Improving Glycemic Control

L.A. McKeown

August 25, 2025

News Opinion CV Team Dispatch

August 2025 Dispatch for the CV Team

L.A. McKeown

August 22, 2025

News Daily News

Oral GLP-1 Drug Yields 12% Weight Loss in Nondiabetic Patients With Obesity

L.A. McKeown

August 07, 2025

News Daily News

Glipizide, Commonly Used Sulfonylurea, Linked to Greater CV Risks

Michael O'Riordan

August 01, 2025

Advertisement

Nearly 150 Million US Adults Eligible for CKM Syndrome Meds

Previewing 30-Year ASCVD Risk May Open Door to Earlier Treatment

JACC Debuts Data Digest on CV Health in the United States

Weight Regained Within 18 Months of Stopping GLP-1 Drugs

Year in Review: Top Prevention Stories of 2025

Year in Review: Women’s Heart Health in the Spotlight

SURPASS-CVOT Published: Large Trial Confirms CVD Efficacy of Tirzepatide

Patients With Obesity Get Biggest Benefit from Evolocumab: FOURIER

Reversal of Childhood Overweight May Prevent Later CHD Risks

WHO Endorses Treating Obesity in Adults With GLP-1s

October 2025 Dispatch for the CV Team

Semaglutide’s CV Effects Only Partially Tied to Weight Loss: SELECT Analysis

High Aerobic Fitness Linked to Less Chronic Disease in Later Life

Risk Factors Present in Nearly All Patients Who Develop CVD

Better Outcomes and Lower Cost with Bariatric Surgery Over GLP-1s

Half of Patients Stop Semaglutide for Weight Loss by 1 Year

AI-Supported Coaching Shows Promise for Improving Glycemic Control

August 2025 Dispatch for the CV Team

Oral GLP-1 Drug Yields 12% Weight Loss in Nondiabetic Patients With Obesity

Glipizide, Commonly Used Sulfonylurea, Linked to Greater CV Risks

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content